Downregulation of BCL-2 Expression in Lymphoma Cells by BCL-2 ARE-targeted Modified, Synthetic Ribozyme
Cancer Gene Therapy - United Kingdom
doi 10.1038/sj.cgt.7700556
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2003
Authors
Publisher
Springer Science and Business Media LLC